AR128311A1 - Inmunización activa para reducir el dolor osteoarticular, neuropático y en cáncer - Google Patents
Inmunización activa para reducir el dolor osteoarticular, neuropático y en cáncerInfo
- Publication number
- AR128311A1 AR128311A1 ARP230100133A ARP230100133A AR128311A1 AR 128311 A1 AR128311 A1 AR 128311A1 AR P230100133 A ARP230100133 A AR P230100133A AR P230100133 A ARP230100133 A AR P230100133A AR 128311 A1 AR128311 A1 AR 128311A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- pain
- fusion protein
- active immunization
- osteoarticular
- Prior art date
Links
- 230000003053 immunization Effects 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title abstract 2
- 206010058019 Cancer Pain Diseases 0.000 title 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 title 1
- 208000004296 neuralgia Diseases 0.000 title 1
- 230000002981 neuropathic effect Effects 0.000 title 1
- 208000021722 neuropathic pain Diseases 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 3
- 201000008482 osteoarthritis Diseases 0.000 abstract 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 abstract 2
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 2
- 102000015336 Nerve Growth Factor Human genes 0.000 abstract 2
- 102400000096 Substance P Human genes 0.000 abstract 2
- 101800003906 Substance P Proteins 0.000 abstract 2
- 229940053128 nerve growth factor Drugs 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una proteína de fusión recombinante utilizada para la inmunización activa o vacuna en el tratamiento del dolor en un sujeto y un método para la producción de esta. La proteína de fusión recombinante incluye: un factor de crecimiento nervioso (NGF); y sustancia P (SP) o un péptido relacionado con el gen de la calcitonina (CGRP). El dolor puede estar asociado con la osteoartritis (OA), inflamación neurogénica, neuropatía, artritis reumatoide, post-cirugía o cáncer. La invención es particularmente útil para tratar el dolor de OA en animales. Reivindicación 17: El vector recombinante de la reivindicación 16, que comprende una secuencia de ácido nucleico que tiene al menos un 90%, al menos un 95% o al menos un 99% de identidad de secuencia con SEC ID Nº 22, SEC ID Nº 23, SEC ID Nº 24 o SEQ ID Nº 25. Reivindicación 22: Una composición inmunogénica que comprende al menos una proteína de fusión recombinante de cualquiera de las reivindicaciones 1 - 15.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263301873P | 2022-01-21 | 2022-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128311A1 true AR128311A1 (es) | 2024-04-17 |
Family
ID=85157093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100133A AR128311A1 (es) | 2022-01-21 | 2023-01-20 | Inmunización activa para reducir el dolor osteoarticular, neuropático y en cáncer |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR128311A1 (es) |
| WO (1) | WO2023139542A1 (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE77033B1 (en) * | 1989-08-16 | 1997-11-19 | Univ Tulane | Substance P antagonists |
| ME00226B (me) * | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| BRPI0618705B8 (pt) * | 2005-11-14 | 2021-05-25 | Labrys Biologics Inc | anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos |
| AU2008339904A1 (en) * | 2007-12-20 | 2009-07-02 | Cytos Biotechnology Ag | Nerve growth factor conjugates and uses thereof |
| NZ595021A (en) * | 2009-03-12 | 2013-04-26 | Nordic Bioscience As | Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists |
| KR20100136633A (ko) * | 2009-06-19 | 2010-12-29 | 서울대학교산학협력단 | 개의 베타-신경 성장 인자 및 이를 함유하는 개의 신경손상 관련 질환 치료용 수의학적 조성물 |
| EP2859018B1 (en) * | 2012-06-06 | 2021-09-22 | Zoetis Services LLC | Caninized anti-ngf antibodies and methods thereof |
| JP2019528284A (ja) * | 2016-08-17 | 2019-10-10 | ファクター バイオサイエンス インコーポレイテッド | 核酸産物およびその投与方法 |
| BR112021012906A2 (pt) * | 2018-12-31 | 2021-12-28 | United Neuroscience Ltd | Imunógenos de peptídeo que têm como alvo peptídeo relacionado ao gene da calcitonina (cgrp) e formulações dos mesmos para prevenção e tratamento de enxaqueca |
-
2023
- 2023-01-20 WO PCT/IB2023/050517 patent/WO2023139542A1/en active Search and Examination
- 2023-01-20 AR ARP230100133A patent/AR128311A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023139542A1 (en) | 2023-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024786A2 (pt) | Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada | |
| MX2021001599A (es) | Moleculas de acido nucleico y sus usos para la terapia genica no viral. | |
| MX2022010027A (es) | Vacuna 2019-ncov (sars-cov-2). | |
| PT87562A (pt) | Procede de expression de la proapolipoproteine a-i humaine | |
| AR112057A1 (es) | Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b | |
| AR128311A1 (es) | Inmunización activa para reducir el dolor osteoarticular, neuropático y en cáncer | |
| CL2020000295A1 (es) | Métodos de terapia génica del factor viii (fviii) | |
| AR123788A1 (es) | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas | |
| CN114316030B (zh) | 一种透皮吸收性的i型重组胶原蛋白及其用途 | |
| ECSP23056133A (es) | Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal | |
| PE20230487A1 (es) | Variantes de alfa-galactosidasa humana | |
| Sandee et al. | Combination of Dsb coexpression and an addition of sorbitol markedly enhanced soluble expression of single‐chain Fv in Escherichia coli | |
| PE20240915A1 (es) | Composiciones y metodos para tratar la enfermedad de fabry | |
| KR20160055940A (ko) | 단백질 추출 방법 | |
| PE20230826A1 (es) | Peptidos y combinaciones de peptidos para uso en inmunoterapia contra la infeccion por sars-cov-2 | |
| PE20221663A1 (es) | Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano | |
| Piez et al. | Homology between the α1 and α2 chains of collagen | |
| AR126464A1 (es) | Agentes para el tratamiento de cánceres positivos para cldn6 | |
| BR112022004601A2 (pt) | Sequências de extensão n-terminal para expressão de peptídeos terapêuticos recombinantes | |
| EP3263710A1 (en) | Production of activated clostridial neurotoxins | |
| AR123961A1 (es) | Composiciones y métodos para el tratamiento de la celiaquía | |
| CN114316029A (zh) | 高透皮吸收性肽及通过该肽的重复构建的重组胶原蛋白 | |
| MX2023002080A (es) | Vector de poxviridae recombinante que expresa moleculas coestimuladoras. | |
| CN113667009A (zh) | 一种三螺旋结构胶原及其制备方法 | |
| AR126727A1 (es) | Composición y método para tratar la neuropatía óptica hereditaria de leber causada por la mutación nd4 |